← Eichor
Study identifier: NCT07417969 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

"Effect of Albumin Combined With Furosemide in Critically Ill Patients With Fluid Overload: Impact on Urine Output and Renal Function"

Condition: Urine Output Decreased  ·  Sponsor: Jose J Zaragoza, MD MSc

PhaseNA
Planned participants56
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

This study aims to compare the effectiveness of furosemide alone versus the combination of furosemide plus albumin in critically ill adult patients with fluid overload. The trial evaluates whether co-administration of albumin enhances diuretic response compared with standard furosemide therapy. The primary outcomes include urine output at 2 hours, changes in renal perfusion markers, and biochemical parameters. Secondary outcomes include changes in mean arterial pressure, electrolyte balance, and renal resistance index. The study seeks to determine whether adding albumin provides a clinically meaningful improvement in diuresis and renal function compared with furosemide monotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Alina Elizabeth Arechiga Casas, MD  ·  +52 8781360564  ·  alieliac26@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

76000Querétaro City, Querétaro, MexicoRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07417969